Business Standard

Analysts' corner

Ranbaxy Laboratories & Havells India

Related News

RANBAXY LABORATORIES
Reco price/date: Rs 552/September 3
Current/target price: Rs 568.55/Rs 450
After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

Antique Stock Broking

HAVELLS INDIA
Reco price/date: Rs 550/September 3
Current/target price: Rs 555.25/Rs 680
The stock underperformed the Sensex by 6.0 per cent during the past three months. It is now trading at 12.1 times the 2013-14 estimated price/earnings ratio, which analysts believe is an attractive valuation. Analysts see steady growth in a tough operating environment, a strong balance sheet, improving free cash generation and a potential rise in the dividend payout as strong stock price drivers. JP Morgan thinks the recent guidance cut for Sylvania margins is priced in, and recent forex trends have become favourable. This could help alleviate concern on a further downside to Sylvania's margins. JP Morgan has raised its FY14 estimated earnings per share five per cent. Upgrade to 'Overweight' from 'Neutral'.

JP Morgan

Read more on:   
|

Analysts' corner

Ranbaxy Laboratories & Havells India

After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

RANBAXY LABORATORIES
Reco price/date: Rs 552/September 3
Current/target price: Rs 568.55/Rs 450
After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

Antique Stock Broking

HAVELLS INDIA
Reco price/date: Rs 550/September 3
Current/target price: Rs 555.25/Rs 680
The stock underperformed the Sensex by 6.0 per cent during the past three months. It is now trading at 12.1 times the 2013-14 estimated price/earnings ratio, which analysts believe is an attractive valuation. Analysts see steady growth in a tough operating environment, a strong balance sheet, improving free cash generation and a potential rise in the dividend payout as strong stock price drivers. JP Morgan thinks the recent guidance cut for Sylvania margins is priced in, and recent forex trends have become favourable. This could help alleviate concern on a further downside to Sylvania's margins. JP Morgan has raised its FY14 estimated earnings per share five per cent. Upgrade to 'Overweight' from 'Neutral'.

JP Morgan

image

Read More

Fund managers divided on high beta preference

Riding high on the crest of the reforms wave, the markets touched their highest closing levels since July 2011 during the week under review ...

Recommended for you

Advertisements

Quick Links

Market News

Today's picks- 27 April 2015

Nifty, Bank Nifty, Cairn & Bharti Airtel

Pulses, oilseeds trade gets relief from stock limits in Maharashtra

However, prices are likely to rise, given the possibility of stock building by large traders

CME, ICE plan exchanges at GIFT City IFSC

Looking to partner exchanges that have shown interest

BSE moves 122 cos on Vadodara SE to dissemination board

Among the vanishing companies are Addi Commercial Enterprises, Anand Dairy, Baroda Dying, Gujarat Apparels, Zen Shaving and Rainbow Housing ...

Sensex, Nifty close below 200-DMAs

FII selling, weak corporate earnings weigh

 

Back to Top